1. Home
  2. CIK vs IMUX Comparison

CIK vs IMUX Comparison

Compare CIK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

HOLD

Current Price

$2.52

Market Cap

136.1M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$12.93

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIK
IMUX
Founded
N/A
2016
Country
United States
United States
Employees
N/A
66
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.1M
152.6M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
CIK
IMUX
Price
$2.52
$12.93
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$36.00
AVG Volume (30 Days)
773.0K
634.4K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$0.51
52 Week High
$3.01
$13.30

Technical Indicators

Market Signals
Indicator
CIK
IMUX
Relative Strength Index (RSI) 43.30 77.19
Support Level $2.44 $0.74
Resistance Level $3.00 $13.30
Average True Range (ATR) 0.04 1.05
MACD -0.00 -0.22
Stochastic Oscillator 33.33 76.22

Price Performance

Historical Comparison
CIK
IMUX

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: